| Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update |
41 |
| KASL clinical practice guidelines for management of chronic hepatitis B |
34 |
| Epidemiology of liver cancer in South Korea |
30 |
| Recent research trends and updates on nonalcoholic fatty liver disease |
19 |
| Unmet need in chronic hepatitis B management |
14 |
| Prevention and management of gastroesophageal varices |
13 |
| Clinical usefulness of psoas muscle thickness for the diagnosis of sarcopenia in patients with liver cirrhosis |
11 |
| Microbiota, a key player in alcoholic liver disease |
11 |
| Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B |
11 |
| KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications |
10 |
| Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend |
10 |
| Radiomics and radiogenomics of primary liver cancers |
9 |
| Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C |
8 |
| Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm? |
8 |
| Epidemiology of alcoholic liver disease in Korea |
7 |
| Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entercavir and tenofovir |
7 |
| Pathologic differential diagnosis of metastatic carcinoma in the liver |
6 |
| Detect or not to detect very early stage hepatocellular carcinoma? The western perspective |
6 |
| 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C |
6 |
| Interferon-free treatment for hepatitis C virus infection induces normalization of extrahepatic type I interferon signaling |
6 |
| Strategic application of radiotherapy for hepatocellular carcinoma |
5 |
| Appropriate treatment modality for solitary small hepatocellular carcinoma: Radiofrequency ablation vs. resection vs. transplantation? |
5 |
| Ultraselective conventional transarterial chemoembolization: When and how? |
5 |
| The association of leptin with severity of non-alcoholic fatty liver disease: A population-based study |
5 |
| Picroside II attenuates fatty acid accumulation in HepG2 cells via modulation of fatty acid uptake and synthesis |
5 |
| Discussion on critical points for a tailored therapy to cure hepatitis C virus infection |
4 |
| Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients |
4 |
| Underlying liver disease and advanced stage liver cancer are associated with elevated neutrophil-lymphocyte ratio |
4 |
| Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients |
4 |
| Endoscopic treatment or balloon-occluded retrograde transvenous obliteration is safe for patients with esophageal/gastric varices in Child-Pugh class C end-stage liver cirrhosis |
4 |
| Cardiac diastolic dysfunction predicts poor prognosis in patients with decompensated liver cirrhosis |
4 |
| Role of liver transplantation in severe alcoholic hepatitis |
4 |
| Adefovir-induced Fanconi syndrome associated with osteomalacia |
4 |
| Comparison of surgical resection versus transarterial chemoembolization with additional radiation therapy in patients with hepatocellular carcinoma with portal vein invasion |
4 |
| Evolution of glomerular filtration rates and neutrophil gelatinase-associated lipocalin during treatment with direct acting antivirals |
4 |
| Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: Comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL |
3 |
| Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study |
3 |
| Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease |
3 |
| Resection plane-dependent error in computed tomography volumetry of the right hepatic lobe in living liver donors |
3 |
| Serum matrix metalloproteinase-1 level represents disease activity as opposed to fibrosis in patients with histologically proven nonalcoholic steatohepatitis |
3 |
| Current epidemiology and clinical characteristics of autoimmune liver diseases in South Korea |
3 |
| Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter? |
3 |
| Severe acute alcoholic hepatitis and liver transplant: A never-ending mournful story |
3 |
| Characterization and evaluation of liver fibrosis grade in patients with chronic hepatitis B virus infection and normal transaminases |
3 |
| Risk assessment of hepatocellular carcinoma development for indeterminate hepatic nodules in patients with chronic hepatitis B |
3 |
| Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure |
3 |
| Sarcopenia: Ammonia metabolism and hepatic encephalopathy |
3 |
| Gadoxetic acid-enhanced magnetic resonance imaging: Hepatocellular carcinoma and mimickers |
3 |
| Safety margin of embolized area can reduce local recurrence of hepatocellular carcinoma after superselective transarterial chemoembolization |
3 |
| Are there differences in risk factors, microbial aspects, and prognosis of cellulitis between compensated and decompensated hepatitis C virus-related cirrhosis? |
2 |
